金井 隆典 (カナイ タカノリ)

Kanai, Takanori

写真a

所属(所属キャンパス)

医学部 内科学教室(消化器) (信濃町)

職名

教授

メールアドレス

メールアドレス

その他の所属・職名 【 表示 / 非表示

  • 医学部, 医学部, 教授

免許・資格 【 表示 / 非表示

  • 日本がん治療認定機構暫定教育医

  • 日本肝臓学会認定肝臓専門医

  • 日本消化器内視鏡学会専門医

  • 日本消化器病学会指導医

  • 日本消化器病学会認定医

全件表示 >>

 

研究キーワード 【 表示 / 非表示

  • ディスバイオーシス

  • プロバイオティクス

  • 炎症性腸疾患

  • 腸内細菌

 

論文 【 表示 / 非表示

  • Difference in the clinical characteristic and prognosis of colitis-associated cancer and sporadic neoplasia in ulcerative colitis patients

    Mutaguchi M., Naganuma M., Sugimoto S., Fukuda T., Nanki K., Mizuno S., Hosoe N., Shimoda M., Ogata H., Iwao Y., Kanai T.

    Digestive and Liver Disease (Digestive and Liver Disease)  51 ( 9 ) 1257 - 1264 2019年09月

    ISSN  15908658

     概要を見る

    © 2019 Editrice Gastroenterologica Italiana S.r.l. Background: Although various studies have been conducted on colitis-associated cancer (CAC), few have assessed the differences in the clinical and endoscopic features, treatment, and prognosis of CAC and sporadic neoplasia (SN) in the inflamed mucosa of ulcerative colitis (UC) patients. Aims: To compare the characteristics of CAC and SN within the previously or currently inflamed mucosa. Methods: Between 1997 and 2017, we retrospectively analyzed the endoscopic chart data of 348 colonic lesions from 266 UC patients. Non-dysplastic lesions and lesions located outside the inflamed mucosa were excluded. The diagnosis of CAC or SN was confirmed by conventional histopathological and immunohistochemical evaluation of p53 and Ki67. Results: In total, 74 patients with CAC (97 lesions) and 46 with SN (58) were enrolled. The proportions of patients with a younger age of onset of UC, with chronic persistent UC, and with severe inflamed mucosa were significantly higher in the CAC group. In the SN group, no flat lesions were found, whereas 26% of the lesions in the CAC group were flat. Sixteen patients died during a median follow-up of 6.1 years (interquartile range (IQR) 1.8–11.1)in the CAC group, whereas 1 patient died during a median follow-up 3.2 years(IQR 1.4–4.6) in the SN group. Mortality from colorectal cancer was significantly higher (P = 0.015) in the CAC group (12/68; 17.6%) than in the SN group (1/44; 2.3%). The 5-year survival rate was 100% in the SN group and 97% in the CAC group for lesions located in the mucosa or submucosa. Conclusion: Recognizing differences in the characteristics of CAC and SN within the inflamed mucosa is critical to avoid unnecessary total colectomy in patients with SN.

  • Pharmacological effects of TAK-828F: an orally available RORγt inverse agonist, in mouse colitis model and human blood cells of inflammatory bowel disease

    Igaki K., Nakamura Y., Tanaka M., Mizuno S., Yoshimatsu Y., Komoike Y., Uga K., Shibata A., Imaichi H., Takayuki S., Ishimura Y., Yamasaki M., Kanai T., Tsukimi Y., Tsuchimori N.

    Inflammation Research (Inflammation Research)  68 ( 6 ) 493 - 509 2019年06月

    ISSN  10233830

     概要を見る

    © 2019, Springer Nature Switzerland AG. Objective and design: To evaluate the potency of RORγt blockade for treatment of Inflammatory Bowel Disease (IBD), the efficacy of TAK-828F, a novel RORγt inverse agonist, in anti-TNF-α mAb non-responsive mouse colitis model and effect of TAK-828F on IL-17 production in peripheral mononuclear blood cells (PBMCs) of anti-TNF-α naive and treatment-failure patients of IBD was investigated. Methods and results: The colitis model showed Th17-dependent pathogenicity and response to anti-IL-12/23p40 monoclonal antibody (mAb), but no response to anti-TNF-α mAb. In the model, TAK-828F, at oral dosages of 1 and 3 mg/kg, inhibited progression of colitis and reduced the immune reaction that characterize Th17 cells. Anti-IL-17A mAb showed neither efficacy nor change in the T cell population and colonic gene expression in the model. In the normal mouse, a 4-week treatment of TAK-828F at 30 mg/kg did not severely reduce lymphocyte cell counts in peripheral and intestinal mucosa, which was observed in RORγ−/− mice. TAK-828F strongly inhibited IL-17 gene expression with IC50 values from 21.4 to 34.4 nmol/L in PBMCs from anti-TNF mAb naive and treatment-failure patients of IBD. Conclusions: These results indicate that RORγt blockade would provide an effective approach for treating refractory patients with IBD by blocking IL-23/Th17 pathway.

  • The association between environmental factors and the development of Crohn's disease with focusing on passive smoking: A multicenter case-control study in Japan

    Kondo K., Ohfuji S., Watanabe K., Yamagami H., Fukushima W., Ito K., Suzuki Y., Hirota Y., Motoya S., Sakuraba H., Ishiguro Y., Sasaki I., Suzuki K., Fukuda K., Saruta M., Shinozaki M., Shimizu T., You A., Nagahori M., Watanabe M., Kanai T., Iizuka B., Watanabe T., Kobayashi K., Kunisaki R., Sugita A., Ishige T., Miura S., Hokari R., Hanai H., Goto H., Ando T., Tanida S., Joh T., Mizoshita T., Sasaki M., Kitamura K., Umegae S., Fujiyama Y., Ando A., Shimizu S., Yoshioka K., Kitano A., Aomatsu K., Naito Y., Yoshida M., Ooi M., Matsumoto T., Fukunaga K., Iimuro M., Ikeuchi H., Ishihara S., Tanaka S., Ueno Y., Matsui T., Yano Y., Yamasaki H., Mitsuyama K., Yamamoto S., Tsubouchi H., Sugimura K., Tenjin T.

    PLoS ONE (PLoS ONE)  14 ( 6 )  2019年06月

     概要を見る

    © 2019 Kondo et al. Background The number of patients with Crohn's disease (CD) in Japan has recently been increasing. We examined the association between environmental factors and the development of CD in Japanese focusing on passive smoking. Methods We conducted a multicenter case-control study and compared the environmental factors of 93 cases who were newly diagnosed with CD to the environmental factors of 132 controls (hospital-, age-, and sex-matched patients with other diseases). The odds ratio (OR) of each factor for the development of CD and the 95% confidence interval (CI) were calculated using a logistic regression model. The association between the details of passive smoking history and the development of CD was examined for those who had an active smoking history "no". Odds ratios of number of passively smoked cigarettes (per day), time of passive smoking (per day) and period of passive smoking (year) were calculated using "passive smoking 'No'" as a reference. Results History of appendicitis, family history of inflammatory bowel disease, and active smoking history were not significantly associated with the development of CD. Drinking history showed a decreased OR for the development of CD (0.39, 0.19-0.77). "Passive smoking Yes" showed significantly increased OR (2.49, 1.09-5.73). Regarding the association between passive smoking and the development of CD, the OR increased as the number of cigarettes per day, smoking time per day, and smoking duration increased, and there was a dose-response relationship (trend P = 0.024, 0.032, 0.038). Conclusions The association between environmental factors and the development of CD among Japanese was examined by case-control study. It was suggested that the passive smoking history may be associated to the development of CD.

  • How Can We Assess "Complete Healing" Beyond Endoscopic Remission?

    Fukuda T., Naganuma M., Kanai T.

    Inflammatory bowel diseases (Inflammatory bowel diseases)  25 ( 6 )  2019年05月

  • Risk factors associated with pseudoaldosteronism in patients with chronic hepatitis: A retrospective cohort study

    Komatsu A., Yoshino T., Suzuki T., Nakamura T., Kanai T., Watanabe K.

    Basic and Clinical Pharmacology and Toxicology (Basic and Clinical Pharmacology and Toxicology)  124 ( 5 ) 607 - 614 2019年05月

    ISSN  17427835

     概要を見る

    © 2018 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society) Glycyrrhizin is used to treat chronic hepatitis, but it also plays an important role in pseudoaldosteronism. Multidrug resistance-associated protein 2 is important for glycyrrhizin excretion. Dysfunction of this transporter increases the serum levels of direct bilirubin, glycyrrhizin and its metabolites. Hence, elevated direct-bilirubin levels could predict the risk of pseudoaldosteronism. This study aimed to evaluate the relationship between elevated direct-bilirubin levels and hypokalaemia, which is the most sensitive marker of pseudoaldosteronism. This retrospective cohort study was conducted in a Japanese university hospital. The occurrence of hypokalaemia is defined as a serum potassium level of ≤3.5 mEq/L after the administration of a glycyrrhizin-containing medication, and a further decline of ≥0.5 mEq/L or an increase of ≥0.5 mEq/L after discontinuing the glycyrrhizin-containing medication was examined in patients with chronic hepatitis between January 2009 and December 2015. This analysis involved 1392 patients, including 596 women. Hepatitis C virus infections were the most common cause of chronic hepatitis in this study. Seventy-nine patients received glycyrrhizin (exposed group; mean age: 60.5 ± 14.2) and 1313 did not receive glycyrrhizin (control group; mean age: 58.3 ± 15.8 years). Synergistic effects of glycyrrhizin-containing medications and elevated direct-bilirubin levels were associated with hypokalaemia. Elevated direct-bilirubin levels and hypoalbuminaemia were associated with hypokalaemia in the exposed group. Older age, female sex, high daily glycyrrhizin dosage, longer duration of glycyrrhizin intake, and potassium-lowering medications were not associated with hypokalaemia after the model adjustment. Elevated direct-bilirubin levels and hypoalbuminaemia may predict pseudoaldosteronism caused by glycyrrhizin.

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

全件表示 >>

総説・解説等 【 表示 / 非表示

  • Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study (PLoS ONE (2019) 14:2 (e0212989) DOI: 10.1371/journal.pone.0212989)

    Motoya S., Watanabe K., Ogata H., Kanai T., Matsui T., Suzuki Y., Shikamura M., Sugiura K., Oda K., Hori T., Araki T., Watanabe M., Hibi T.

    PLoS ONE (PLoS ONE)  14 ( 4 )  2019年04月

     概要を見る

    © 2019 Motoya et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. An incorrect version of S2 File was published in error. This article was republished on April 2, 2019 to correct for this error. Please download this article again to view the correct version.

  • Correction: Clinical utility of novel ultrathin single-balloon enteroscopy: A feasibility study (Endoscopy (2018) (50) DOI: 10.1055/a-0656-5622)

    Takabayashi K., Hosoe N., Miyanaga R., Fukuhara S., Kimura K., Mizuno S., Naganuma M., Yahagi N., Ogata H., Kanai T.

    Endoscopy (Endoscopy)  51 ( 5 )  2019年

    ISSN  0013726X

     概要を見る

    © Georg Thieme Verlag KG, Stuttgart - New York. In the above-mentioned article, the name of the author Kaoru Takabayashi has been corrected. This was corrected in the online version on August 24, 2018.

  • Innate lymphoid cells in organ fibrosis

    Mikami Y., Takada Y., Hagihara Y., Kanai T.

    Cytokine and Growth Factor Reviews (Cytokine and Growth Factor Reviews)  42   27 - 36 2018年08月

    ISSN  13596101

     概要を見る

    © 2018 Elsevier Ltd Innate lymphoid cells (ILCs) are a recently identified family of lymphoid effector cells. ILCs are mainly clustered into 3 groups based on their unique cytokine profiles and transcription factors typically attributed to the subsets of T helper cells. ILCs have a critical role in the mucosal immune response through promptly responding to pathogens and producing large amount of effector cytokines of type 1, 2, or 3 responses. In addition to the role of early immune responses against infections, ILCs, particularly group 2 ILCs (ILC2), have recently gained attention for modulating remodeling and fibrosis especially in the mucosal tissues. Herein, we overview the current knowledge in this area, highlighting roles of ILCs on fibrosis in the mucosal tissues, especially focusing on the gut and lung. We also discuss some new directions for future research by extrapolating from knowledge derived from studies on Th cells.

  • Reply

    Kanai T., Naganuma M.

    Gastroenterology (Gastroenterology)  155 ( 2 ) 578 - 579 2018年08月

    ISSN  00165085

研究発表 【 表示 / 非表示

  • 粘膜下層深部への浸潤を認めたバレット腺癌の一例

    金井 隆典

    第106回日本消化器内視鏡学会関東支部例会, 2018年06月

  • ガストリン著明上昇を伴わない自己免疫性胃炎を背景とした神経内分泌腫瘍の1例

    金井 隆典

    第106回日本消化器内視鏡学会関東支部例会, 2018年06月

  • 肝移植待機における門脈血栓治療と静脈瘤治療

    金井 隆典

    第54回日本肝臓学会総会, 2018年06月

  • Mayo内視鏡スコア1を有する臨床的寛解潰瘍性大腸炎患者に対する治療介入の意 義に関する検討

    金井 隆典

    第95回日本消化器内視鏡学会総会, 2018年05月

  • 潰瘍性大腸炎における青黛の副作用に関する検討

    金井 隆典

    第104回日本消化器病学会総会, 2018年04月

全件表示 >>

競争的資金等の研究課題 【 表示 / 非表示

  • 腸管AhRワールドの解明

    2019年02月
    -
    2021年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 金井 隆典, 国際共同研究加速基金(国際共同強化(B)), 補助金,  代表

  • 難治性クローン病に対する神経難病治療薬OCH-NCNPの有用性および安全性を検証する医師主導治験

    2015年04月
    -
    2018年03月

    国立研究開発法人 日本医療研究開発機構, 金井 隆典, 代表

  • ヒト疾患糞便移植マウスモデルを用いた炎症性腸疾患ディスバイオーシスの解明

    2015年04月
    -
    2018年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 金井 隆典, 基盤研究(A), 補助金,  代表

  • プロバイオティクス優位腸内細菌パターン形成ワクチンの開発

    2015年04月
    -
    2017年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 金井 隆典, 挑戦的萌芽研究, 補助金,  代表

     研究概要を見る

    炎症性腸疾患発症に関して特異的な腸内細菌への絞込みを目的とし、健常人(HC)、原発性硬化性胆管炎合併潰瘍性大腸炎(PSC/UC)患者糞便を無菌マウスへ移植したマウス(HCマウス、PSC/UCマウス)を作成し、PSC/UCマウスでは肝臓内Th17細胞の集積を認めた。PSC/UCマウスのみでKlebsiella pneumonia, Proteus mirabilis, Enterococcus gallinarumの同定培養に成功。Q-PCR法にて解析しPSC/UC患者に高頻度にこれらの腸内細菌が検出。ある特定の悪玉菌の腸内細菌が腸管外病変へ関与する事を見い出し、発展性が期待できる成果と考える。

受賞 【 表示 / 非表示

  • 慶應義塾大学医学部坂口洋光記念医学研究助成賞

    2009年

  • 三越医学研究助成賞

    2008年

  • 慶應義塾大学医学部三師会 北島賞

    2008年

  • 日本応用酵素協会研究奨励賞

    2005年

  • 全米生理学会カンファレンス Travel Award

    2004年

全件表示 >>

 

担当授業科目 【 表示 / 非表示

  • 臨床研究学特論

    2019年度

  • 内科学臨床実習アドバンスト

    2019年度

  • 臨床腫瘍学特論

    2019年度

  • 内科学特論

    2019年度

  • 内科ケーススタディー

    2019年度

全件表示 >>

 

所属学協会 【 表示 / 非表示

  • 日本癌学会

     
  • 日本臨床腫瘍学会

     
  • 日本食品免疫学会

     
  • 東京都医師会

     
  • 日本炎症性腸疾患研究会

     

全件表示 >>

委員歴 【 表示 / 非表示

  • 2015年
    -
    継続中

    評議員, 日本門脈亢進症学会

  • 2015年
    -
    継続中

    理事, 日本無菌生物ノートバイオロジー学会

  • 2014年
    -
    継続中

    評議員, 日本臨床腸内微生物学会

  • 2014年
    -
    継続中

    特定疾患事業 「神経難病治療薬OCH-NCNPの炎症性腸疾患を対象とした医師主導治験へ向けた製剤確保、治験プロトコール作成、治験相談の実施」, 厚生労働省

  • 2013年
    -
    継続中

    財団評議員, 日本消化器病学会

全件表示 >>